Cancer Vaccines, RNA Deals, Saudi Biotech
Kilder
- Endpoints: Nouscom raises $135M in Series D for lead cancer vaccine
- Fierce Biotech: Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate - Fierce Biotech
- BioSpace: Nouscom Raises €120 Million ($135 Million) in Oversubscribed Series D Financing and will Present Long-Term Cancer Interception Clinical Data in Lynch Syndrome Carriers at ESMO - BioSpace
- BioPharma Dive: Disc’s once-spurned rare disease drug to get a second chance at approval
- STAT: STAT+: China moves to restrict foreign biotech acquisitions
- Endpoints: Veradermics' oral Rogaine wins again at growing hair in late-stage trial
- Reuters: Veradermics' oral hair-loss drug shown to boost hair growth in late-stage study - Reuters
- Raps: Recon: German Merck acquires Silence Therapeutics for $1.3B; China's Hansoh Pharma strikes $15B drug deal with Roche - RAPS
- Endpoints: Sanofi taps new startup ScionxBio for long-acting RNA
- BioPharma Dive: From strategy to scale: How Saudi Arabia is building a biotech ecosystem
- Ramaonhealthcare: From strategy to scale: How Saudi Arabia is building a biotech ecosystem - RamaOnHealthcare
- wikimedia: Photo by Rhoda Baer (Photographer) / Wikimedia Commons / Public domain
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.